| Primary information |
|---|
| sequence ID | Seq_6975 |
| Peptide sequence | SEETKENEGFTVTAEG |
| CancerPDF_ID | CancerPDF_ID943, CancerPDF_ID1492, CancerPDF_ID9603, |
| PMID | 19795908,21136997,21533267 |
| Protein Name | Complement C3,Complement C3,Complement C3 |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN,CO3_HUMAN |
| Fluid | Plasma,Serum,Serum |
| M/Z | 864.38,1726.75335,864.35 |
| Charge | 2,1,2 |
| Mass (in Da) | NA,NA,NA |
| fdr | NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC-MS-MS/MS,LC/MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),LC-ESI-MS,Multiple Reaction Monitoring |
| Labelled/Label Free | Labelled,Label Free,Label Free |
| FDR | less than 7%,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID943, CancerPDF_ID1492, CancerPDF_ID9603, |
| p-Value | NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT |
| Length | 16,16,16 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,SwissProt Database,Swissprot Database (57.4) |
| Modification | NA,NA,NA |
| Number of Patients | "42 normal, 28 patients",30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | NA,Leave One out Cross validation,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |